Eight new drugs were recommended for approval at the CHMP's latest meeting with cancer immunotherapies from Merck & Co and BristolMyers Squibb BMS headlining.Merck's Keytruda pembrolizumab was given a green light to treat advanced melanoma an indic...
↧